OBIO® Reports
Based on a survey of industry leaders, supervisors and early-career talent who have been part of OBIO’s Health to Business Bridge (H2BB™) program, the report describes how H2BB™ has addressed the health science industry’s need for job ready talent.
The report is based on a comprehensive industry consultation with leaders from coast-to-coast, who provided their feedback on their experiences in 2020 and recommendations for how Canada’s health science industry can become a global leader in the bioeconomy.
Bridging the Talent Gap: Reporting on Year 2 describes the results of the first seven cohorts of early career talent that has completed the program.
OBIO’s 2019 report describes an early adopter model to facilitate the evaluation and adoption of innovative health technologies in Ontario health organizations.
OBIO’s report, Realizing the Promise of Health Care Innovation: Increasing Value for the Patient, Health System and Economy, was published in 2013 and is a product of the Ontario Bioscience Economic Strategy Team (OBEST®), an initiative launched by OBIO to address the challenges faced by Ontario’s human health technology and bioscience industry.
OBIO’s 2018 Industry Consultation reports five recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB™) business internship program. This report describes how H2BB™ addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
The “Tackling the Anchor Company Challenge Summit”, assembled industry, academic, government and investment leaders committed to working together to create a mandate of action for anchoring health science companies in Ontario.
In 2017, the Ontario Bioscience Innovation Organization convened a working group (‘OBIO Tax Policy Working Group’, OTPWG) of health science industry leaders and tax experts from academia and the private sector to examine Canada’s tax incentives and their effectiveness in stimulating growth in the health science industry.
OBIO has provided feedback to the Ministry of Research Innovation and Science on the the Province's request to recruit Ontario's First Chief Science Officer.
"The Ontario Bioscience Innovation Organization (OBIO) strongly believes that the supply chain of the future must incorporate a formal approach to creating pathways for the adoption and procurement of innovation, to benefit the people of Ontario from both a health and economic perspective."
2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level.
Gail Garland, CEO
OBIO
For the full strategic review, click here
There are compelling reasons for a strong, Canadian healthcare industry. Canada has opportunities but there are barriers to success. This report presents industry’s solutions.
Over the past several months, OBESTTM has engaged >200 senior representatives from major stakeholder groups across Ontario’s life-sciences sector. The 6-month strategic planning process has resulted in defined priorities and a plan for robust growth and commercial viability of the province’s bioscience industry.
Ontario's life sciences companies continue to be challenged by the slow global economic recovery. Restrictions in the availability of capital continue to constrain this sector's ability to ensure Ontario's 'human capital' provides its greatest return on our societal investment.